ClinicalTrials.gg
RecruitingNCT07708350Updated Oct 21, 2026

Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease

A Phase 1 interventional study of autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein and Sequencing Assay for Variant rs114518452 in Sickle Cell Disease and Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), sponsored by Daniel Bauer. Recruiting at 1 site in United States. Open to participants aged 13 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Daniel Bauer · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 21, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
13 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Planned enrollment
485th of 559
5 · median 31
Started
2026
with 28 others
Phase 1
98 of 733
13 open now
Primary completion
2028-12
later than 133 of 182 live
Registered
728th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 485th largest by planned enrollment of the 559 interventional ones that give a count, is one of 29 that started in 2026, is one of 98 in phase 1, reaches primary completion later than 133 of the 182 other live ones, and was the 728th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

128 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 13 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

A promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine that uses genetic material (mostly deoxyribonucleic acid (DNA)) from the patient to treat his or her own disease. In gene therapy, the investigators introduce new genetic material in order to fix or replace a diseased gene, with the goal of curing the disease. The procedure is similar to a bone marrow transplant, in that the patient's malfunctioning blood stem cells are reduced or eliminated using chemotherapy, but it is different because instead of using a different person's (donor) blood stem cells for the transplant, the patient's own blood stem cells are given back after the new genetic material has been introduced into those cells. This approach has the advantage of eliminating any risk of Graft-Versus-Host Disease (GVHD), reducing the risk of graft rejection, and may also allow less chemotherapy to be utilized for the conditioning portion of the transplant procedure. The method used to fix or replace a diseased gene is called gene editing. A person's own cells are edited using a specialized biological medicine that has been formulated for use in human beings.

Fetal hemoglobin (HbF) is a healthy, non-sickling kind of hemoglobin. Investigators have recently discovered a gene called BCL11A that is very important in the control of fetal hemoglobin expression. Increasing the expression of this gene in sickle cell patients could increase the amount of fetal hemoglobin while simultaneously reducing the amount of sickle hemoglobin in their blood, and therefore potentially cure the condition.

Read the detailed description

This is a non-randomized, single center, open-label, pilot safety and feasibility study involving a single infusion of autologous bone marrow derived CD34+ hematopoietic stem cells (HSPCs) electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein. Accrual will be a maximum of 5 evaluable subjects with sickle cell disease (SCD).

Ages ≥18-35 years: Stratum 1 (n=3) Ages ≥13-18 years: Stratum 2 (n=2)

After meeting eligibility criteria, patients will be enrolled. Patients will receive blood transfusions for a period of 3 months prior to hematopoietic stem cell collection, with a goal of achieving a Hemoglobin S (HbS) level of ≤ 30% by the time of mobilization. Patients will undergo peripheral stem cell mobilization and have their cells collected by apheresis. The collected cells of each subject will be split into 2 portions; one portion for gene editing, and one portion set aside as a back-up product in the event a rescue treatment is needed. Patients may undergo multiple rounds of collection if sufficient numbers of cells are not obtained with the first collection.

Patients will undergo a standard work-up for autologous bone marrow transplantation prior to proceeding with conditioning and infusion of their gene-edited cells. Patients will receive myeloablative conditioning with busulfan administered on days -5 to -2, prior to the infusion of edited cells. The edited cells will be infused intravenously.

Patients will be followed for 24 months after the infusion of their gene edited cells.

The study is unable to enroll patients residing outside of the United States.

03

Conditions studied

  • Sickle Cell Disease
  • Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)

Browse trials for

Keywords

  • gene therapy
  • stem cell transplant
  • bone marrow transplant
  • autologous hematopoietic stem cell transplant
  • gene editing
  • hematopoietic stem cell transplant
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
13 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of either a) sickle cell disease with genotype HbSS, HbS/B0 thalassemia, HbSD, or HbSO
  2. Age 13-35 years.
  3. Clinically severe disease, defined as: The presence of one or more of the following clinical complications: i) Minimum of two episodes of acute chest syndrome (ACS) in the 2 years before study entry. ii) History of three or more episodes of severe pain events requiring a visit to a medical facility and treatment with parenteral opioids in the 2 years before study entry.
  4. Adequate hematologic parameters including:

    a. White blood cell (WBC) count within the range of 2.5 - 25.0 x 109 /L b. count within the range of 150 - 700 x 109 /L

  5. Adequate organ function and performance status:

    1. performance status ≥70%
    2. Serum creatinine \</=1.5 times the for age, and calculated or (GFR) \</= 60 mL/min/1.73 m2.
    3. Direct ≤ 2.0 mg/dL
    4. Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) (corrected for ), (FEV1), Forced Vital Capacity (FVC) >50% of predicted
    5. >40% or shortening fraction >25%
  6. Failure of hydroxyurea therapy due to lack of clinical improvement, inability to tolerate due to side effects (e.g., myelosuppression, gastrointestinal symptoms, or hepatic enzyme elevations) or not clinically indicated (such as in a patient on a chronic transfusion regimen). Clinical criteria (per above) must be met despite taking hydroxyurea for greater than or equal to 6 months, unless not indicated or not tolerated. Patients taking hydroxyurea who still meet all inclusion criteria are eligible for the trial. Hydroxyurea should be discontinued when transfusions prior to gene therapy begin.
  7. Confirmed sickle cell disease diagnosis by molecular genetic testing.
  8. No Human Leukocyte Antigen (HLA) genotypically-identical related appropriate bone marrow donor available.
  9. Parental/guardian/patient signed .
  10. Willingness to return for follow-up for 15 years.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have concomitant condition or illness including, but not limited to:

    1. Uncontrolled infection, such as current febrile illness, infection requiring parenteral antibiotics, or systemic fungal infection.
    2. Active .
    3. Active complication of underlying hemoglobinopathy that would place the patient at unacceptable risk for participation, in the judgment of the Investigators.
    4. Major surgery in the past 30 days.
    5. Medical/psychiatric illness/social situations that would limit compliance with study requirements as determined by the treating physician.

      • to administration of conditioning medication (busulfan).

3. Subjects who have undergone or autologous hematopoietic stem cell transplant previously.

4. Either or both of the following findings on screening bone marrow aspirate/: a) diagnosis of myelodysplastic syndrome (MDS) based on morphology and/or cytogenetics (based on WHO definitions) or b) pathogenic mutation in any gene on the Rapid Heme Panel (RHP), a next-generation targeted sequencing clinical assay for hematologic malignancy associated mutations.

5. For SCD patients:

  1. Severe cerebral vasculopathy (defined by occlusion or stenosis in the circle of Willis; or presence of Moyamoya disease)
  2. Receiving a chronic transfusion regimen for primary or secondary stroke prophylaxis. (Note: patients with a history of abnormal transcranial Doppler (TCD) who have transitioned from transfusions to hydroxyurea for stroke prophylaxis are also not eligible for the study. Most recent TCD must be within one year of screening for patients up to 16 years old.)
  3. History of overt stroke or any neurologic event lasting > 24 hours. (Note: patients with imaging evidence of silent stroke but not on a chronic transfusion regimen are not excluded.) 6. Severe iron overload that is deemed to be grounds for exclusion based on the opinion of the Principal Investigator.

    7. Known positive (HIV) serology or HIV nucleic acid testing, or positive serology for (HCV), (HBV), or Human T-Lymphotropic Virus (HTLV).

    8. Known acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on prior biopsy.

    9. Receipt of an study drug or procedure within 90 days of study enrollment.

    10. Pregnancy, or breastfeeding in a postpartum female, or absence of adequate for fertile subjects. Females of must agree to use a medically acceptable method of birth control such as oral contraceptive, intrauterine device, barrier and spermicide, or contraceptive implant/injection from Screening through at least 6 months after drug product infusion. Male subjects must agree to use effective contraception (including condoms) from Screening through at least 6 months after drug product infusion.

    11. An assessment by the Investigators that the subject will not comply with the study procedures outlined in the study protocol, or that, as determined by the investigators and/or transplant physician, the subject has any other condition rendering the subject ineligible for Hematopoietic Stem Cell Transplantation (HSCT) or other study procedures.

    12. Patients carrying at least one cytosine (C) alternate allele at the SNP site rs114518452, chr2:210530659-210530659 (GRCh38/hg38), where guanine (G) is the reference allele.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Sickle Cell Disease

    Biological: autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein · Device: Sequencing Assay for Variant rs114518452

Interventions

  • Biologicalautologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein

    autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein

  • DeviceSequencing Assay for Variant rs114518452

    Device used to carry out the diagnostic testing for exclusion criteria number 12

06

What researchers measure

Primary outcomes

  1. Primary engraftment

    Successful hematopoietic reconstitution after conditioning (defined by absolute neutrophil count (ANC) greater than or equal to 0.5 x 10\^9 /L for three consecutive days without growth factor support), achieved by day 42 after day 0 of stem cell infusion (i.e., "primary engraftment").

    Time frame: 42 days

Secondary outcomes

  1. Concentration of Hemoglobin

    Total hemoglobin (in g/dL), hemoglobin fractions (A, F, and S in g/dL), percent HbF, and percent F cells

    Time frame: 24 months

  2. Platelet Engraftment

    Platelet engraftment (defined as platelet count ≥20,000/L without transfusion for 7 days by day +42 after stem cell infusion)

    Time frame: 42 days

  3. Severe vaso-occlusive crises

    Change from baseline in incidence of severe vaso-occlusive crises (requiring emergency department visit or hospital admission)

    Time frame: 24 months

  4. Acute chest syndrome

    Change from baseline in incidence of acute chest syndrome

    Time frame: 24 months

  5. Stroke

    Change from baseline in incidence of stroke

    Time frame: 24 months

  6. Splenic sequestration

    Change from baseline in incidence of splenic sequestration

    Time frame: 24 months

  7. Transfusion requirement

    Change from baseline in transfusion requirement (in mL/kg) after day +100 post infusion

    Time frame: 24 months

  8. Reticulocyte Count

    Change from baseline reticulocyte count

    Time frame: 24 months

  9. Concentration of Bilirubin

    Change from baseline bilirubin

    Time frame: 24 months

  10. Concentration of Lactate dehydrogenase (LDH)

    Change from baseline lactate dehydrogenase (LDH)

    Time frame: 24 months

  11. Quality of Life in Adult Subjects

    Quality of life, assessed by administration of the 36-Item Short Form Survey (SF-36) (on a scale of 0-100, with 100 being the highest, 0 being the lowest) tool for adult subjects.

    Time frame: 24 months

  12. Quality of Life in Pediatric Subjects

    Quality of life, assessed by administration of the Pediatric Quality of Life Inventory (PedsQL) (on a scale of 0-100, with 100 being the highest, 0 being the lowest) survey tool to the patient (or parents of young children) for subjects under 18 years old.

    Time frame: 24 months

Other outcomes

  1. Safety Outcome: Death

    Occurrence of death

    Time frame: 24 months

  2. 14. Safety Outcome: Malignancy, abnormal bone marrow cytogenetics, or myelodysplasia

    Occurrence of malignancy, abnormal bone marrow cytogenetics, or myelodysplasia

    Time frame: 24 months

  3. Safety Outcome: Serious adverse events

    Number of serious adverse events

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.

Of 58 phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 16, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2030
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
Boston Children's Hospital is now Recruiting
Oct 21, 2026
Eligibility
Maximum age 40 Years→35 Years; 4 inclusion criteria edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedAge 13-4035 years.
  • EditedSerum creatinine </=1.5 times the upper limit of normal for age, and calculated creatinine clearance or Glomerular Filtration Rate (GFR) </= 60 mL/min/1.73 m2.
  • EditedDiffusing Capacity of the Lungs for Carbon Monoxide (DLCO) (corrected for hemoglobin), Forced Expiratory Volume in 1 Second (FEV1), Forced Vital Capacity (FVC) >50% of predicted
  • EditedNo Human Leukocyte Antigen (HLA) genotypically-identical related appropriate bone marrow donor available.
Exclusion criteria
  • Edited7. Known positive Human Immunodeficiency Virus (HIV) serology or HIV nucleic acid testing, or positive serology for Hepatitis C (HCV), Hepatitis B (HBV), or Human T-Lymphotropic Virus (HTLV).
  • Edited11. An assessment by the Investigators that the subject will not comply with the study procedures outlined in the study protocol, or that, as determined by the investigators and/or transplant physician, the subject has any other condition rendering the subject ineligible for Hematopoietic Stem Cell Transplantation (HSCT) or other study procedures.
Oct 21, 2026
Secondary outcomes
5 edited, 1 added
What changed in the outcomes
  • EditedConcentration of HemoglobinTime frame: 24 months
  • EditedReticulocyte countCountTime frame: 24 months
  • EditedConcentration of BilirubinTime frame: 24 months
  • EditedConcentration of Lactate dehydrogenase (LDH)Time frame: 24 months
  • EditedQuality of Life in Adult SubjectsTime frame: 24 months
  • AddedQuality of Life in Pediatric SubjectsTime frame: 24 months
Oct 21, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Boston Children's Hospital · Boston, United StatesContact added g•••@childrens.harvard.edu · •••1954
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Recruiting
    Boston Children's Hospital is now Recruiting
    Eligibility Maximum age 40 Years→35 Years; 4 inclusion criteria edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAge 13-4035 years.
    • EditedSerum creatinine </=1.5 times the upper limit of normal for age, and calculated creatinine clearance or Glomerular Filtration Rate (GFR) </= 60 mL/min/1.73 m2.
    • EditedDiffusing Capacity of the Lungs for Carbon Monoxide (DLCO) (corrected for hemoglobin), Forced Expiratory Volume in 1 Second (FEV1), Forced Vital Capacity (FVC) >50% of predicted
    • EditedNo Human Leukocyte Antigen (HLA) genotypically-identical related appropriate bone marrow donor available.
    Exclusion criteria
    • Edited7. Known positive Human Immunodeficiency Virus (HIV) serology or HIV nucleic acid testing, or positive serology for Hepatitis C (HCV), Hepatitis B (HBV), or Human T-Lymphotropic Virus (HTLV).
    • Edited11. An assessment by the Investigators that the subject will not comply with the study procedures outlined in the study protocol, or that, as determined by the investigators and/or transplant physician, the subject has any other condition rendering the subject ineligible for Hematopoietic Stem Cell Transplantation (HSCT) or other study procedures.
    Secondary outcomes 5 edited, 1 added
    What changed in the outcomes
    • EditedConcentration of HemoglobinTime frame: 24 months
    • EditedReticulocyte countCountTime frame: 24 months
    • EditedConcentration of BilirubinTime frame: 24 months
    • EditedConcentration of Lactate dehydrogenase (LDH)Time frame: 24 months
    • EditedQuality of Life in Adult SubjectsTime frame: 24 months
    • AddedQuality of Life in Pediatric SubjectsTime frame: 24 months
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Boston Children's Hospital · Boston, United StatesContact added g•••@childrens.harvard.edu · •••1954
    + 3 other changes: verification date, date precision and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07708350
Lead sponsor
Daniel Bauer
Responsible party
Daniel Bauer (Associate Professor Pediatrics, Boston Children's Hospital, Boston Children's Hospital) — Sponsor-investigator
First posted
Jul 16, 2026
Start date
Aug 1, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 21, 2026

Study contacts

Emily Morris
Contact
gene.therapy@childrens.harvard.edu
631-355-8724

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion